Ankur Drugs and Pharma, a Mumbai based Rs 675 crore company, has posted all round performance during the year ended March 2008. The company's net profit increased smartly by 91.9 per cent to Rs 62.80 crore from Rs 32.73 crore in the previous year. Its net sales increased by 80.5 per cent to Rs 673.65 crore from Rs 373.24 crore. With better growth in profits, its earning per share worked out to Rs 53.19 as against Rs 34.1 in the last period.

The profit before interest, depreciation and taxation improved by 82.3 per cent to Rs 106.29 crore from Rs 58.29 crore despite significant rise in material cost and staff cost. The raw material consumption cost increased to Rs 531.53 crore from Rs 296.14 crore in the previous year. Its staff cost also moved up by 47.8 per cent to Rs 10.79 crore from Rs 7.30 crore.

The interest burden increased substantially to Rs 24.45 crore from Rs 12.92 crore, a growth of 89.2 per cent. The depreciation charges stood at Rs 7.14 crore as against Rs 6.02 crore. The profit before tax touched to Rs 74.70 crore from Rs 39.36 crore.

The promoters lower their equity stake to 27.8 per cent during 2007-08 from 33.32 per cent in the last year.